Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[2-[2-[3-[[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]methyl]-2,5-difluorophenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC51H67ClF2N10O11S |
InChIKeyOPHJDILLGXTILW-MSEXGENUSA-N |
CAS Registry- |